Meridian Bioscience Inc. (VIVO): Price and Financial Metrics
Meridian Bioscience Inc. (VIVO)
Today's Latest Price: $18.74 USD
Updated Nov 27 1:00pm
Add VIVO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
VIVO Stock Summary
- In terms of twelve month growth in earnings before interest and taxes, Meridian Bioscience Inc is reporting a growth rate of 84.84%; that's higher than 86.81% of US stocks.
- As for revenue growth, note that VIVO's revenue has grown 26.19% over the past 12 months; that beats the revenue growth of 82.92% of US companies in our set.
- The volatility of Meridian Bioscience Inc's share price is greater than that of 83.99% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Meridian Bioscience Inc, a group of peers worth examining would be ULBI, CTS, SCL, CRTO, and HTGM.
- Visit VIVO's SEC page to see the company's official filings. To visit the company's web site, go to www.meridianbioscience.com.
VIVO Stock Price Chart Interactive Chart >
VIVO Price/Volume Stats
| Current price | $18.74 | 52-week high | $26.58 |
| Prev. close | $17.76 | 52-week low | $5.51 |
| Day low | $17.68 | Volume | 363,931 |
| Day high | $18.86 | Avg. volume | 726,331 |
| 50-day MA | $17.91 | Dividend yield | N/A |
| 200-day MA | $15.70 | Market Cap | 807.24M |
Meridian Bioscience Inc. (VIVO) Company Bio
Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is based in Cincinnati, Ohio.
VIVO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $18.74 | $6.78 | -64% |
Below please find a table outlining a discounted cash flow forecast for VIVO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Meridian Bioscience Inc ranked in the 25th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Meridian Bioscience Inc ended up being:
- The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.01%; that's greater than only 23.15% of US stocks we're applying DCF forecasting to.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -65% |
| 1% | -65% |
| 2% | -64% |
| 3% | -64% |
| 4% | -64% |
| 5% | -63% |
Want more companies with a valuation profile/forecast similar to that of Meridian Bioscience Inc? See A, ABC, BIO, LGND, and SNN.
Loading social stream, please wait...